(Total Views: 750)
Posted On: 01/04/2021 11:01:52 AM
Post# of 153983
In addition to the eIND criteria correction, subtle changes were made to the call agenda. Here is the original list:
1) BLA submissions to Health Canada, MHRA, EMA, and US FDA
2) HIV prevention trial/monotherapy trial
3) Potential revenue from HIV and manufacturing forecast
4) HIV Cure - amfAR
5) EUA submission timelines to same four agencies for COVID-19
6) Long-hauler clinical trial and potential data readout timelines
7) NASH trial and potential interim analysis timeline
Cancer trial Breakthrough Therapy designation potential timelines
9) GvHD trial status
10) Stroke/MS new trials in 2021
11) NASDAQ uplisting status
And here is the updated list:
1) BLA/MAA submissions to Health Canada, MHRA, EMA, and US FDA
2) HIV prevention trial/monotherapy trial
3) Potential revenue from HIV and manufacturing forecast
4) HIV Cure - amfAR
5) EUA submission timelines to same four agencies for COVID-19, if CD12 Trial results are supportive of an EUA
6) Long-hauler clinical trial and potential data readout timelines
7) NASH trial and potential interim analysis timeline
Cancer trial Breakthrough Therapy designation potential timelines
9) GvHD trial status
10) Stroke/MS new trials in 2021
11) NASDAQ uplisting status
1) BLA submissions to Health Canada, MHRA, EMA, and US FDA
2) HIV prevention trial/monotherapy trial
3) Potential revenue from HIV and manufacturing forecast
4) HIV Cure - amfAR
5) EUA submission timelines to same four agencies for COVID-19
6) Long-hauler clinical trial and potential data readout timelines
7) NASH trial and potential interim analysis timeline
Cancer trial Breakthrough Therapy designation potential timelines 9) GvHD trial status
10) Stroke/MS new trials in 2021
11) NASDAQ uplisting status
And here is the updated list:
1) BLA/MAA submissions to Health Canada, MHRA, EMA, and US FDA
2) HIV prevention trial/monotherapy trial
3) Potential revenue from HIV and manufacturing forecast
4) HIV Cure - amfAR
5) EUA submission timelines to same four agencies for COVID-19, if CD12 Trial results are supportive of an EUA
6) Long-hauler clinical trial and potential data readout timelines
7) NASH trial and potential interim analysis timeline
Cancer trial Breakthrough Therapy designation potential timelines 9) GvHD trial status
10) Stroke/MS new trials in 2021
11) NASDAQ uplisting status
(12)
(0)
